Deals in Depth: September 2023

Six $1bn+ alliances were penned in September. Topping the list was a potential $3.46bn multi-year deal between Nurix Therapeutics and Seagen to advance a new class of medicines called Degrader-Antibody Conjugates for use in cancer. The collaboration will focus on an innovative approach to combine two powerful technologies to target cancer – antibody-drug conjugation and targeted protein degradation – with the goal of creating drugs with new mechanisms of action as well as improved specificity and anti-cancer activity.

Deals In Depth

 In the top September M&A by deal value, Enovis entered into a definitive agreement to acquire LimaCorporate for an enterprise value of approximately $851.48m in cash and stock. Lima is a privately held orthopedic company focused on restoring motion through a portfolio of implant solutions. The company specializes in additive manufacturing, including its proprietary trabecular titanium (TT) technology. The addition of Lima will give Enovia a complementary portfolio of proven surgical solutions and technologies, including 3D printed TT and a comprehensive revision offering. Financing reached $12.5bn in biopharma, $233m in device, and $487m in diagnostics.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By 

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By 

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.